Advances in the treatment of amyloidosis

New England Journal of Medicine

Volumn 356, Issue 23, 2007, Pages 2413-2415

  Rajkumar, S Vincent ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CHLORAMBUCIL; COLCHICINE; DEXAMETHASONE; DIFLUNISAL; EPRODISATE; GLYCOSAMINOGLYCAN; MELPHALAN; UNCLASSIFIED DRUG;

AMYLOIDOSIS; CHEMOTHERAPY; CLINICAL TRIAL; DRUG ACTIVITY; EDITORIAL; HUMAN; LIVER TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 34249982105     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe078027     Document Type: Editorial

References (13)

1. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000;130:88-98.
2. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006;81:693-703. [Erratum, Mayo Clin Proc 2006;81:1509.]
3. Dember LM, Hawkins PN, Hazenberg BPC, et al. Eprosidate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349-60.
4. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8.
5. Gertz MA, Lacy MQ, Dispenzieri A, Hayman S, Kumar S. Transplantation for amyloidosis. Curr Opin Oncol 2007;19:136-41.
6. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9.
7. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552-6. [Erratum, Am J Med 2006;119: 191.]
8. Sharma P, Perri RE, Sirven JE, et al. Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transpl 2003;9:1273-80.
9. Olofsson BO, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002;73:745-51.
10. Tojo K, Sekijima Y, Kelly JW, Ikeda S. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 2006;56:441-9.
11. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-9.
12. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28.
13. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis. Best Pract Res Clin Haematol 2005;18:709-27.